Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1994 May;93(5):2251-7.
doi: 10.1172/JCI117223.

Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells

Affiliations
Comparative Study

Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells

A Bergamini et al. J Clin Invest. 1994 May.

Abstract

We have investigated the effects of cystamine on the replication of human immunodeficiency virus (HIV) in human lymphocytes and macrophages, the natural targets of HIV in vivo. Treatment of chronically infected macrophages with cystamine, at a concentration (500 microM) that did not show any cytotoxic or cytostatic effects, strongly decreased (> 80%) HIV-p24 antigen production and completely abolished the production of infectious viral particles. Cystamine does not affect viral transcription, translation or protein processing; indeed, all HIV proteins are present in a pattern similar to that of nontreated cells. Instead, cystamine interferes with the orderly assembly of HIV virions, as shown by electron microscopy analysis, that reveals only defective viral particles in treated cells. Moreover, suppression of HIV replication, due to the inhibition of proviral DNA formation was observed in acutely infected lymphocytes and macrophages pretreated with cystamine. These results show that cystamine potently suppresses HIV replication in human cells by contemporaneously blocking at least two independent steps of the viral life cycle, without affecting cell viability, suggesting that this compound may represent a new possibility towards the treatment of HIV-1 infection.

PubMed Disclaimer

References

    1. Lancet. 1986 Mar 15;1(8481):575-80 - PubMed
    1. J Exp Med. 1990 Apr 1;171(4):1043-56 - PubMed
    1. J Clin Invest. 1986 May;77(5):1712-5 - PubMed
    1. Res Commun Chem Pathol Pharmacol. 1990 Feb;67(2):289-92 - PubMed
    1. Annu Rev Immunol. 1990;8:169-94 - PubMed

Publication types

MeSH terms